Seminar | ‘Pull’ incentives: How should we value and contract for new antibiotics?
The importance of “pull” incentives to ensure that new antibiotics are available to help fight anti-microbial resistance (AMR): how should we value and contract for new antibiotics?
Antibiotic resistance is increasingly rapidly and new antibiotics are urgently needed. Health Technology Assessment (HTA) and payer bodies need to be ready to respond appropriately to new antibiotics coming to market. This session will explore how the full range of benefits of antibiotics can be captured in HTA, and how we should pay for them when their value may depend on restricting use.
Presenter: Dr Chris Henshall
Date: Thursday 1 February
Time: 12:45 – 14:00
Venue: LG4 (Weston Room), Tavistock Place
Watch now or watch later
Use this link to watch the seminar live, or afterwards.
Dr Chris Henshall
Chris Henshall works as an independent consultant, advising governments, public and private sector organisations on health, research and innovation policy. He is a Visiting Fellow at the Office of Health Economics in London.
Chris was the Founding President of Health Technology Assessment International (HTAi), Chair of the HTAi Policy Forum from 2005-7 and 2011-16, and Chair of the HTAi Asia HTA Policy Forum from 2013-16. Other recent positions include Board Director of Alberta Innovates (the public funder of research and innovation in the Province of Alberta, Canada), Associate Professor in the Health Economics Research Group at Brunel University London, and Honorary Fellow at the Centre for Health Economics at the University of York (UK).
In the course of a career in health research and innovation, Chris has worked for the Health Promotion Research Trust, the UK Medical Research Council, the Department of Health and the NHS in England (where as Under Secretary he was involved in establishing the NHS R&D Budget, the NHS HTA Programme and the National Institute for Health and Clinical Excellence – NICE), the Department of Trade and Industry (where he was responsible for UK science and innovation policy and funding), and the University of York (where as Pro Vice Chancellor he was responsible for promoting enterprise and innovation and links with the economy, government and businesses at home and overseas).Back